Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the many advances in genetics, genomics and systems biology, 'validation' of a target is not achieved until therapeutic efficacy is demonstrated by a drug candidate. Volume 46 of this series reviews the medicinal chemistry aimed at six diverse targets from which important new medicines are emerging: * HIV integrase (discovery of the first-in-class inhibitor drug raltegravir)* 11 ...
Read More
Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the many advances in genetics, genomics and systems biology, 'validation' of a target is not achieved until therapeutic efficacy is demonstrated by a drug candidate. Volume 46 of this series reviews the medicinal chemistry aimed at six diverse targets from which important new medicines are emerging: * HIV integrase (discovery of the first-in-class inhibitor drug raltegravir)* 11-beta-Hydroxysteroid dehydrogenase (new approach to glucocorticoid regulation)* Nicotinic a7 choline receptor (agonists and positive allosteric modulators). * Bradykinin receptor (new approach to pain therapy)* Histone deacetylase (new drugs for cancer)* 5-HT2c receptor modulators (various CNS indications)
Read Less
Add this copy of Progress in Medicinal Chemistry: 46: Volume 46 to cart. $54.00, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2008 by Elsevier Science.
Add this copy of Progress in Medicinal Chemistry: Volume 46 to cart. $268.90, new condition, Sold by Booksplease rated 4.0 out of 5 stars, ships from Southport, MERSEYSIDE, UNITED KINGDOM, published 2008 by Elsevier Science.